This autumn, the U.S. Secretary of Health and Human Services (HHS) has finally begun negotiating prices for 10 Medicare Part D drugs as...

The growth of the generics market has produced impressive economic benefits for the United States. The Association for Accessible...

At The J. Molner Company, company values are not just a business buzzword. We define company values as tangible, measurable, and ...

Employees who feel engaged, motivated, and aligned with the values of their workplace are more likely to contribute to the success of ...

Summer is a season perfect for relaxation, as the Estonian tradition of “summer days” attests. Summer days are events organized...

Recent updates in FDA guidelines open a cost-saving opportunity for pharma companies looking to fulfill dermatological bioequivalence...

At The J. Molner Company, we have revamped our portfolio of services to support pharmaceutical companies navigating FDA reporting...

Across the EU, demand is surging as pharmacy shelves become empty. Can future shortages be prevented? Let’s take a look. Recently,...

Pharmaceutical companies are now dealing with inflation, a problem that used to be considered long gone. With rising rent and food...

As the Great Resignation hit businesses around the world, clever managers addressed their teams’ burnout with a novel solution:...

One common obstacle for laboratory productivity is the prevalence of old analytical methods. While new technologies keep coming up, many...

The price of generic pharmaceutical products has been a point of contention during the last couple of decades for small manufacturers,...

As the founder of the J. Molner Company, I knew that starting a business around the other side of the world could be daunting - there are...

The last couple of years have taught the public terms such as rate of contagion, exponential growth, and percentage of effectiveness. It...

As a response to the current global pandemic, many countries have awoken to the fragility of domestic supply chains for drugs. For many,...

There is one thing both regulatory bodies and pharmaceutical industry leaders agree on: the supply chain of generic drugs is not 100%...

The keys to staying competitive in the pharmaceutical supply chain have changed since the appearance of COVID-19. Here at The J. Molner...